Phospho-Chk1 (Ser317) Recombinant Rabbit Monoclonal Antibody (Chk1S317-G1), APC, Invitrogen™
Manufacturer: Fischer Scientific
Select a Size
| Pack Size | SKU | Availability | Price |
|---|---|---|---|
| Each of 1 | PIMA537326-Each-of-1 | In Stock | ₹ 19,758.00 |
PIMA537326 - Each of 1
In Stock
Quantity
1
Base Price: ₹ 19,758.00
GST (18%): ₹ 3,556.44
Total Price: ₹ 23,314.44
Antigen
Phospho-Chk1 (Ser317)
Classification
Monoclonal
Conjugate
APC
Gene
Chek1
Gene Alias
C85740; Cell cycle checkpoint kinase; checkpoint kinase 1; checkpoint kinase 1 homolog; checkpoint kinase-1; Checkpoint, S. pombe, homolog of, 1; CHEK1; CHK1; CHK1 checkpoint homolog; Chk1-S; homolog of Chk1-S; HRD1 Protein; rad27; rad27 homolog; serine/threonine protein kinase CHK1; serine/threonine-protein kinase Chk1; Synoviolin; YBR1742; YBR274W
Host Species
Rabbit
Purification Method
Protein A/G
Regulatory Status
RUO
Gene ID (Entrez)
1111, 12649
Content And Storage
4° C
Form
Liquid
Applications
Flow Cytometry
Clone
Chk1S317-G1
Formulation
PBS with 0.20% BSA and 0.09% sodium azide
Gene Accession No.
O14757, O35280
Gene Symbols
Chek1
Immunogen
A synthetic phospho-peptide corresponding to residues surrounding Ser317 of human phospho Chk1.
Quantity
10 Tests
Primary or Secondary
Primary
Target Species
Human, Mouse
Product Type
Antibody
Isotype
IgG κ
Related Products
Description
- CHEK1 (CHK1) is a serine/threonine protein kinase involved in preventing replication when DNA integrity is compromised
- CHK1 is a key mediator in the DNA damage-induced checkpoint network
- CHK1 is an evolutionarily conserved protein kinase that functions to ensure genomic integrity upon genotoxic stress
- When the G2 or S checkpoint is abrogated by the inhibition of CHK1, p53-deficient cancer cells undergo mitotic catastrophe and eventually apoptosis, whereas normal cells are still arrested in the G1 phase
- Thus, CHK1 inhibitors can preferentially potentiate the efficacy of DNA damaging agents in cancer cells, and Chk1 is an attractive therapeutic target for cancer treatment, especially since approximately 50% of all human cancers are p53-deficient.